1. Amant, F., Moerman, P., Neven, P., Timmerman, D., Van Limbergen, E., and Vergote, I. (2005). Endometrial cancer. Lancet 366, 491–505.
2. Morice, P., Leary, A., Creutzberg, C., Abu-Rustum, N., and Darai, E. (2016). Endometrial cancer. Lancet 387, 1094–1108.
3. Burke, W.M., Orr, J., Leitao, M., Salom, E., Gehrig, P., Olawaiye, A.B., Brewer, M., Boruta, D., Villella, J., Herzog, T., et al. (2014). Endometrial cancer: A review and current management strategies: Part I. Gynecol. Oncol. 134, 385–392.
4. Burke, W.M., Orr, J., Leitao, M., Salom, E., Gehrig, P., Olawaiye, A.B., Brewer, M., Boruta, D., Herzog, T.J., and Shahin, F.A. (2014). Endometrial cancer: A review and current management strategies: Part II. Gynecol. Oncol. 134, 393–402.
5. Bokhman, J. V. (1983). Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 15, 10–17.
6. Darvishian, F., Hummer, A.J., Thaler, H.T., Bhargava, R., Linkov, I., Asher, M., and Soslow, R.A. (2004). Serous Endometrial Cancers That Mimic Endometrioid Adenocarcinomas. Am. J. Surg. Pathol. 28, 1568–1578.
7. Murray, S.K., Young, R.H., and Scully, R.E. (2000). Uterine Endometrioid Carcinoma with Small Nonvillous Papillae: An Analysis of 26 Cases of a Favorable-Prognosis Tumor To Be Distinguished from Serous Carcinoma. Int. J. Surg. Pathol. 8, 279–289.
8. Murali, R., Davidson, B., Fadare, O., Carlson, J.A., Crum, C.P., Blake Gilks, C., Irving, J.A., Malpica, A., Matias-Guiu, X., Glenn McCluggage, W., et al. (2019). High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations. Int. J. Gynecol. Pathol. 38, S40–S63.
9. Brinton, L.A., Felix, A.S., McMeekin, D.S., Creasman, W.T., Sherman, M.E., Mutch, D., Cohn, D.E., Walker, J.L., Moore, R.G., Downs, L.S., et al. (2013). Etiologic heterogeneity in endometrial cancer: Evidence from a Gynecologic Oncology Group trial. Gynecol. Oncol. 129, 277–284.
10. Zannoni, G.F., Vellone, V.G., Arena, V., Prisco, M.G., Scambia, G., Carbone, A., and Gallo, D. (2010). Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical–pathological and immunohistochemical study. Virchows Arch. 457, 27–34.
11. Getz, G., Gabriel, S.B., Cibulskis, K., Lander, E., Sivachenko, A., Sougnez, C., Lawrence, M., Kandoth, C., Dooling, D., Fulton, R., et al. (2013). Integrated genomic characterization of endometrial carcinoma. Nature 497, 67–73.
12. Bell, D.W. (2014). Novel genetic targets in endometrial cancer. Expert Opin. Ther. Targets 18, 725–730.
13. Liang, S., and Lu, X. (2018). Research on the Inhibitory Effect of FAT-1 on Endometrial Cancer Cell Proliferation. Am. J. Pharm 37, 903–910.
14. Shia, J., Black, D., Hummer, A.J., Boyd, J., and Soslow, R.A. (2008). Routinely assessed morphological features correlate with microsatellite instability status in endometrial cancer. Hum. Pathol. 39, 116–125.
15. Yamashita, H., Nakayama, K., Ishikawa, M., Nakamura, K., Ishibashi, T., Sanuki, K., Ono, R., Sasamori, H., Minamoto, T., Iida, K., et al. (2018). Microsatellite